DNA RNA and Cells

31 Mar 2020 Spray-On Gene Therapy With RenovaCare SkinGun™ in New Study Underway at King’s College London
30 Mar 2020 Clinical outcomes of Mesoblast’s cell therapy in end-stage ischemic heart failure presented at American College of Cardiology virtual scientific sessions
30 Mar 2020 Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
29 Mar 2020 AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
27 Mar 2020 uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
27 Mar 2020 Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
26 Mar 2020 VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
24 Mar 2020 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
24 Mar 2020 Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors
24 Mar 2020 First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
24 Mar 2020 AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
24 Mar 2020 Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
23 Mar 2020 Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures
23 Mar 2020 Sorrento and Smartpharm to collaborate to develop novel gene-encoded antibody vaccine intended to protect against COVID-19
23 Mar 2020 AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
20 Mar 2020 AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
19 Mar 2020 Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
19 Mar 2020 Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Therapeutic Candidates in the fields of Oncology, Infectious Disease, and Immune Disorders
19 Mar 2020 NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
18 Mar 2020 GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified Off-the-shelf Natural Killer Cells in 'Nature Scientific Reports'
18 Mar 2020 Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
16 Mar 2020 GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
13 Mar 2020 Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
13 Mar 2020 FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections
13 Mar 2020 Artugen Therapeutics Announces First Patient Dosed with ART24, Artugen’s First Clinical Product Candidate for Prevention of Recurrence of Clostridium Difficile Infection

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top